NYSE:MLSS
MILESTONE SCIENTIFIC INC.
A clinical-stage biopharmaceutical firm pursuing novel therapies for serious diseases through a proprietary discovery platform with minimal current revenue generation.
Key Metrics
Investment Thesis
Bull Case
If any of the company's pipeline assets reach late-stage clinical trials or generate significant licensing deals, the current low market cap could provide substantial upside potential. The narrowing net loss trend from -$8.8M in 2022 to -$4.7M in 2024 suggests improving operational leverage before commercialization. Strategic partnerships with major pharmaceutical companies could provide non-dilutive funding and accelerate asset development.
Bear Case
The company faces immediate existential risk given only $3.3M in cash against a burn rate that requires regular capital raises, likely resulting in shareholder dilution. Persistent negative profitability with no commercial product sales indicates high dependency on volatile venture capital markets for survival. High research and development costs of nearly $859K annually with no current revenue generation create significant downside risk if clinical trials fail.
About MILESTONE SCIENTIFIC INC.
Milestone Scientific Inc. (MLSS) is a biopharmaceutical company focused on developing novel therapeutics for serious diseases such as cancer, fibrosis, and immune disorders. The company leverages proprietary drug discovery platforms to generate pipeline assets primarily for potential licensing or strategic partnerships rather than traditional commercialization. Operating within the competitive biotech sector, MLSS navigates high R&D expenditures while managing limited cash reserves to extend its operational runway.
Analysis
Management Discussion
Despite a modest revenue increase from $8.8M in 2022 to $9.8M in 2023, the company returned to $8.6M in 2024 while losses narrowed slightly from -$8.8M to -$4.7M over five years. The narrowing loss suggests improved operational efficiency or successful milestone collections, though operating expenses remain elevated at $13.2M versus $8.6M revenue. Cash flow from operations turned negative at -$2.9M while financing activities provided only $0.2M, highlighting a critical need for external capital.
Industry Overview
The biopharmaceutical industry is characterized by high failure rates in drug development, requiring substantial capital investment over many years before any commercial return. Companies often rely on licensing deals to offset R&D costs and manage cash flow until product approval and market entry occur. Competition for research funding and talent is intense, with only a small percentage of early-stage assets reaching market success.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $8.8M | $9.8M | $8.6M |
| Cost of Revenue | $3.9M | $3.0M | $2.2M |
| Gross Profit | $4.9M | $6.8M | $6.4M |
| Operating Expenses | $13.7M | $13.9M | $13.2M |
| Operating Income | $-8.8M | $-7.1M | $-6.8M |
| R&D | $1.2M | $701.4K | $858.8K |
| G&A | $12.5M | $13.1M | $12.3M |
| Stock-Based Comp | $1.5M | $1.5M | $1.3M |
| D&A | $63.8K | $61.9K | $37.4K |
| Depreciation | $14.2K | $13.0K | $7.2K |
| Amortization | $49.7K | $49.3K | $30.2K |
| Other OpEx | $63.8K | $61.9K | $37.4K |
| Non-Operating Income | $54.6K | $125.5K | $2.0M |
| Pre-Tax Income | $-8.8M | $-7.0M | $-4.7M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-8.8M | $-7.0M | $-4.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.8M | $-7.0M | $-4.7M |
| Minority Interest | $-66.7K | $-51.8K | $0 |
| Net to Common | $-8.7M | $-6.9M | $-4.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $13.0M | $10.8M | $9.3M |
| Cash & Equivalents | $8.7M | $3.0M | $3.3M |
| Marketable Securities | $8.7M | $3.0M | $0 |
| Accounts Receivable | $693.7K | $312.7K | $475.4K |
| Inventory | $1.8M | $2.6M | $3.7M |
| Prepaid Expenses | $443.9K | $517.8K | $564.6K |
| Other Current Assets | $-7.4M | $1.4M | $1.3M |
| Long-Term Assets | $731.6K | $577.0K | $510.5K |
| PP&E (Net) | $18.1K | $10.0K | $12.9K |
| Operating Leases | $443.7K | $355.2K | $257.8K |
| Other LT Assets | $269.8K | $211.8K | $239.8K |
| Total Assets | $13.7M | $11.4M | $9.8M |
| Current Liabilities | $3.3M | $3.1M | $3.7M |
| Accounts Payable | $1.1M | — | — |
| Current Leases | $91.7K | $103.4K | $116.3K |
| Other Current Liab | $980.4K | $1.5M | $1.8M |
| Long-Term Liabilities | $396.0K | $282.3K | $220.2K |
| LT Operating Leases | $385.3K | $281.9K | $165.6K |
| Other LT Liab | $10.7K | $434 | $54.7K |
| Total Liabilities | $3.7M | $3.4M | $4.0M |
| Shareholders' Equity | $10.0M | $8.0M | $5.8M |
| Retained Earnings | $-116.4M | $-123.3M | $-128.1M |
| Treasury Stock | $911.5K | $911.5K | $911.5K |
| Total L&E | $13.7M | $11.4M | $9.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-8.8M | $-7.0M | $-4.7M |
| Non-Cash Adjustments | $1.7M | $1.3M | $23.9K |
| Working Capital Changes | $1.0M | $377.5K | $1.8M |
| Cash from Operations | $-6.0M | $-5.3M | $-2.9M |
| Capital Expenditures | $8.5K | — | — |
| Cash from Investing | $-8.5K | $-3.0M | $3.0M |
| Cash from Financing | $-8.5K | $2.6M | $233.8K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-6.0M | $-5.7M | $280.3K |
| Beginning Cash | $14.8M | $8.7M | $3.0M |
| Ending Cash | $8.7M | $3.0M | $3.3M |
Frequently Asked Questions
How does MILESTONE SCIENTIFIC INC. make money?
The company's financial profile suggests operations are heavily concentrated in research and development activities, likely organized by therapeutic areas such as oncology, fibrosis, or immunology. Revenue streams appear to be primarily derived from upfront payments, milestones, or royalties from licensing agreements rather than product sales, given the low revenue relative to operating expenses.
What are the main risks for MLSS?
Significant negative operating cash flow of $2.9M and net loss of $4.7M indicate unsustainable burn rates without new funding or successful commercialization. Limited cash on hand of $3.3M creates immediate liquidity pressure requiring equity dilution or asset sales. High R&D spend of nearly $859K with no current revenue suggests high probability of clinical trial failure or inability to secure partnerships.
What is MLSS's competitive advantage?
Proprietary drug discovery platforms that differentiate its pipeline assets in crowded therapeutic markets. Strategic focus on high-value indications with potential for significant royalty upside upon licensing deals. Lean corporate structure allowing for efficient capital deployment despite current cash burn.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.